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============

While melanoma accounts for approximately 5% of all skin cancers in the United States (US), it is responsible for about 90% of all skin cancer deaths \[[@CR1]--[@CR3]\]. According to the Surveillance, Epidemiology and End Results (SEER) program, the incidence of melanoma has been increasing for the last 30 years. In 2014, there were an estimated 76,100 new cases and 9710 melanoma-associated deaths in the US \[[@CR4]\].

The goals of treatment for melanoma are cure, local control, or palliation, and are mainly determined by the stage of disease. For localized lesions (Stages I and II, American Joint Committee on Cancer, 7th edition) removal of the tumor by wide resection is potentially curative. If there is a loco-regional recurrence following initial surgery, additional surgical attempts can be considered \[[@CR24]\]. At a certain point, patients may be considered unresectable based on the number of failed prior attempts for surgical cure or the technical unfeasibility of additional surgery. For patients with melanoma in-transit (Stage IIIB or IIIC), the goal of treatment is maintenance of local disease control and prevention of disease progression to distant metastases, including visceral metastases (Stage IV) \[[@CR5]\]. For patients with advanced disease, cure after surgery alone is rare. The main treatment modality for Stage IV disease is systemic drug treatment to reduce tumor burden with the aim of prolonging survival and decreasing symptoms \[[@CR6]\].

Isolated limb perfusion (ILP) and isolated limb infusion (ILI) are therapeutic modalities for regional metastatic melanoma with prevalent in-transit disease, which allow high doses of anticancer drugs (usually chemotherapy) to be delivered directly into the circulation of an affected limb, thus minimizing systemic drug exposure and subsequent toxicity. ILP was pioneered by Creech et al. at Tulane University in the 1950s \[[@CR7]\]. Regional concentrations of chemotherapeutic agents 15--25 times higher than those possible with systemic administration can be achieved with ILP in the tumor-bearing extremity. The isolation of the blood vessels of a limb is achieved by clamping and cannulation of the major artery and vein, and application of a tourniquet above the cannulation. ILI, a less elaborate alternative to ILP, was developed at the Sydney Melanoma Unit by Thompson et al. in the 1990s \[[@CR8]\]. ILI differs from ILP in that it does not use an extracorporeal circulation system, making it less expensive and a shorter procedure requiring fewer medical resources. To potentiate the effect of the procedure, infusion or perfusion of the limb is frequently performed using a hyperthermic solution of chemotherapeutic agent (usually melphalan). ILP/ILI is usually performed in an inpatient setting since both procedures require anesthesia and use of an operating room.

ILP/ILI can result in response rates of 30--60% in melanoma patients \[[@CR9]--[@CR11]\]. However, randomized clinical trials comparing ILP/ILI with other treatment modalities are lacking. ILP, as an adjunct to radical surgery, failed to demonstrate an improvement in overall survival in two randomized clinical trials in patients with regional metastatic melanoma \[[@CR12], [@CR13]\].

Currently, ILP/ILI is recommended by the European Society for Medical Oncology (ESMO) and the US National Comprehensive Cancer Network (NCCN) Guidelines as a treatment option for patients with unresectable in-transit melanoma \[[@CR14], [@CR15]\]. ESMO states that "non-resectable in-transit metastases or inoperable primary tumors of the limbs without additional metastases may be treated with ILP using, e.g., melphalan and/or tumor necrosis factor-α". The NCCN states that "for patients with multiple, regional, in-transit metastases, regional chemotherapy by hyperthermic perfusion or infusion is an option". In the US, payers such as Blue Cross Blue Shield Health Plans \[[@CR16]--[@CR18]\], have established a policy that ILP/ILI should meet medical criteria for coverage when used as a therapeutic treatment for unresectable local recurrence of melanoma (i.e., satellite lesions or "in-transit" melanoma).

To date, limited information is available in the literature on patterns of ILP/ILI use and costs. This study aimed to describe patterns of ILP/ILI use and estimate associated costs in patients with regional metastatic melanoma in the US.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

This was a retrospective, observational study using a large administrative claims database from the Truven Health Analytic MarketScan^®^ databases. The MarketScan database contains fully adjudicated patient-level medical and pharmacy claims data for over 40 million commercially insured and Medicare-insured patients in 2014. Data elements drawn from these databases included member demographics (age, gender, residence region, and enrollment), dates of service, care setting, diagnostic codes, procedure codes, and payments.

Study Population {#Sec4}
----------------

Patients with a diagnosis of melanoma (ICD-9-CM: 172.xx, V10.82) who underwent ILP/ILI procedures between January 1, 2002 and March 31, 2013 in an inpatient setting were included in this study. The ILP/ILI procedures were identified by the Current Procedural Terminology (CPT)-4 code 36823, which describes the procedures as "insertion of arterial and venous cannula(s) for isolated extracorporeal circulation and regional chemotherapy perfusion to an extremity, with or without hyperthermia, with removal of cannula(s) and repair of arteriotomy and venotomy sites". Admission and discharge dates were identified for each hospitalization involving an ILP/ILI procedure. At least one claim of melanoma with an ICD-9-CM diagnosis code (principal or secondary) any time between the admission and discharge dates was required to ensure that the ILP/ILI procedure was for melanoma treatment.

Outcome Measures {#Sec5}
----------------

The main outcome measures in this analysis were patterns of ILP/ILI use, length of hospital stay (LOS), and hospitalization costs of ILP/ILI. LOS was calculated based on the number of days between the admission and discharge dates from the hospital. Costs were computed as the combined health plan and patient paid amount, and were adjusted using the annual medical care component of the consumer price index to reflect inflation between 2002 and 2014 \[[@CR19]\].

Results of the analyses are presented descriptively as mean and median values. All data were analyzed using SAS programs organized within SAS^®^ Enterprise Guide version 4.2 (SAS Institute Inc, Cary, NC, USA) and conducted under UNIX using SAS version 9.2.

Independent Variables {#Sec6}
---------------------

Independent variables included both demographic and clinical characteristics based on MarketScan information collected at the time of hospital admission. Demographic characteristics included in the analysis were age, gender, health plan type, Medicare or commercial beneficiaries, region, and year of service. Clinical characteristics included melanoma site, metastatic site, and Charlson Comorbidity Index score (excluding cancers) \[[@CR22], [@CR23]\].

This article does not contain any new studies with human or animal subjects performed by any of the authors.

Results {#Sec7}
=======

Patient Characteristics {#Sec8}
-----------------------

A total of 113 patients met the study criteria and were included in the analysis. Mean patient age was 61.4 years \[standard deviation (SD) 13.8\] and 38.9% of patients were male. The mean baseline Charlson Comorbidity Index score was 0.19% and 34.5% of patients were Medicare beneficiaries.

Overall, 87.6% of patients had primary melanoma of the lower limb, 11.5% of the upper limb, and 0.9% of both the upper and lower limbs; 60.2% had lymph node metastasis and 56.6% had skin metastasis within 1 year prior to the discharge date of the hospitalization. A summary of the patient demographic characteristics is reported in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical characteristics of patients with melanoma who underwent ILP/ILI procedurePatients, *n* (%)\
(*N* = 113)Age, mean (SD), years\
Age categories, years61.4 (13.8) 18--342 (1.8) 35--449 (8.0) 45--5427 (23.9) 55--6438 (33.6) 65--7414 (12.4) 75+23 (20.4)Female69 (61.1)Health plan Comprehensive24 (21.2) HMO7 (6.2) POS1 (0.9) PPO67 (59.3) Other plans14 (12.4)Medicare beneficiaries39 (34.5)Regions Northeast11 (9.7) North Central25 (22.1) South62 (54.9) West12 (10.6) Unknown3 (2.7)Primary melanoma site Lower limb99 (87.6) Upper limb13 (11.5) Both upper and lower limbs1 (0.9)Presence of metastasis^a^ Any metastasis105 (92.9) Liver1 (0.9) Lung3 (2.7) Lymph nodes68 (60.2) Skin64 (56.6)Charlson Comorbidity Index (excluding cancer), mean (SD)0.19 (0.49)Year of service for ILP/ILI procedure 20022 (1.8) 20031 (0.9) 20044 (3.5) 200512 (10.6) 20065 (4.4) 200710 (8.8) 20085 (4.4) 200915 (13.3) 201019 (16.8) 201115(13.3) 201223 (20.4) 20132 (1.8)^a^The site of metastases is not mutually exclusive. It was identified 1 year prior to the discharge date of the hospitalization

Patterns of ILP/ILI Use {#Sec9}
-----------------------

Of the 113 patients identified, the majority (109/113, \[96.5%\]) underwent only one procedure. Four patients (3.5%) underwent multiple ILP/ILI procedures. Of these four patients, three underwent ILP/ILI twice, and one patient underwent three ILP/ILI procedures. The median time between procedures for these four patients was 190 days. The use of ILP/ILI was stable across years, as there was small amount of procedures (1--23) performed between 2002 and 2013.

Length of Hospital Stay and Costs Associated with ILP/ILI {#Sec10}
---------------------------------------------------------

Per ILP/ILI procedure, the mean (±SD) hospital LOS due to ILP/ILI was 5.6 (±3.5) days. The median LOS was 5.0 days and the range was 1--22 days. From 2002 to 2013 inclusive, LOS was generally similar across the years. The mean LOS for patients with Medicare was 6.3 days, compared with 5.1 days for patients with commercial insurance.

The mean cost of ILP/ILI performed in the inpatient setting was US\$36,758 (±27,124) per procedure. The range of the cost varied considerably from US\$8202 to US\$154,008, with a median cost of US\$26,905 (Table [2](#Tab2){ref-type="table"}).Table 2Length of stay and costs associated with ILP/ILI proceduresMean (SD)MedianPercentile75th90th95th99thLength of stay (days)5.6 (3.5)5.07.08.013.020.0Inpatient cost per procedure (2014 USD)36,758 (27,124)27,55647,79575,74193,547110,485

Discussion {#Sec11}
==========

This study provides an assessment of use patterns and costs of ILP and ILI. The mean hospital length of stay for ILP/ILI procedures was 5.6 days and the mean cost was US\$36,758 per procedure. To the best of our knowledge, this is the first study that reports real-world use patterns and costs of ILP/ILI in a regional metastatic melanoma population in the US.

Based on the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP), the average hospital cost (physician cost not included in the report) for a surgical procedure was US\$20,500 in 2013 \[[@CR20]\]. Therefore, the costs of ILP/ILI procedures are higher than those of an average national surgical procedure. Secondly, the LOS and costs associated with ILP/ILI procedures are in line with those associated with major surgery for metastatic melanoma as estimated by Zhao et al. \[[@CR21]\], where the overall mean hospital LOS due to surgery was 4.4 days and the overall mean cost of hospitalization was US\$37,649.

This analysis has limitations. While ILI is currently more common than ILP, there is no separate procedure code (CPT) differentiating ILP from ILI in the claims data. This precludes an analysis of use patterns and costs separately for ILP and ILI. Cost per procedure could be different for ILP and ILI because the ILP technique involves a more technically complex and invasive operative procedure, requiring open surgical cannulation of the vessels at the root of the extremity. In comparison to ILP, ILI is a simplified and minimally invasive operative procedure. Secondly, the study population was composed of commercially insured and Medicare-insured patients, and the patterns and costs of these procedures may not be representative of all patients with regional metastatic melanoma, especially the uninsured or those covered by Medicaid. Comparison of ILP/ILI with other alternative therapies for limb melanoma metastases including electrochemotherapy, local therapies (interleukin, Rose Bengal, electrodessication), and systemic therapies was outside the scope of the current study. This topic warrants further research.

The current study focused only on hospitalization cost associated with ILP/ILI, which can be seen as direct medical costs. Indirect costs associated with ILP/ILI were not examined due to lack of indirect cost information in the database. Considering that metastatic melanoma affects the working age population, indirect costs related to the recovery period at home, concomitant medication such as antibiotics or painkillers, and rehabilitation processes could be considerable and add to the overall costs. Furthermore, the indirect cost associated with complication or morbidity due to ILP/ILI could also be substantial. Thus, the total costs of ILP/ILI to society can be more expensive than said in the healthcare claims data.

Conclusions {#Sec12}
===========

The use of ILP and ILI was associated with long hospital stays and high costs. The results of this study may provide useful source data for the economic evaluation of treatment options for regional metastatic melanoma.
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